Seaport Therapeutics, Inc. (SPTX) — insider trading
Health Care · NASDAQ
Seaport Therapeutics, Inc. (SPTX) has 41 reported SEC Form 4 insider transactions in our data, including 2 open-market purchases among the most recent 41 (latest 2026-06-22).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-22 | HOMBACH ROBERT J. | Director | Open-market purchase | 13,000 | $18.14 | $235.8K | Form 4 |
| 2026-05-04 | PureTech Health plc; PureTech LYT, Inc. | 10% owner | Conversion of derivative (derivative) | 3,031,578 | — | $0 | Form 4 |
| 2026-05-04 | PureTech Health plc; PureTech LYT, Inc. | 10% owner | Conversion of derivative (derivative) | 8,421,052 | — | $0 | Form 4 |
| 2026-05-04 | PureTech Health plc; PureTech LYT, Inc. | 10% owner | Conversion of derivative (derivative) | 40,000,000 | — | $0 | Form 4 |
| 2026-05-04 | PureTech Health plc; PureTech LYT, Inc. | 10% owner | Conversion of derivative | 965,255 | — | — | Form 4 |
| 2026-05-04 | PureTech Health plc; PureTech LYT, Inc. | 10% owner | Conversion of derivative | 2,681,265 | — | — | Form 4 |
| 2026-05-04 | PureTech Health plc; PureTech LYT, Inc. | 10% owner | Conversion of derivative | 12,736,014 | — | — | Form 4 |
| 2026-05-04 | Loebel Antony | Officer (Chief Medical Officer) | Conversion of derivative (derivative) | 63,157 | — | $0 | Form 4 |
| 2026-05-04 | Loebel Antony | Officer (Chief Medical Officer) | Conversion of derivative | 20,109 | — | — | Form 4 |
| 2026-05-04 | ARCH Venture Partners XII, LLC; ARCH Venture Partners XII, L.P.; ARCH Venture Fund XII, L.P.; CRANDELL KEITH; NELSEN ROBERT; Burow Kristina; GILLIS STEVEN | 10% owner | Conversion of derivative (derivative) | 2,681,265 | — | $0 | Form 4 |
| 2026-05-04 | ARCH Venture Partners XII, LLC; ARCH Venture Partners XII, L.P.; ARCH Venture Fund XII, L.P.; CRANDELL KEITH; NELSEN ROBERT; Burow Kristina; GILLIS STEVEN | 10% owner | Conversion of derivative (derivative) | 2,513,686 | — | $0 | Form 4 |
| 2026-05-04 | ARCH Venture Partners XII, LLC; ARCH Venture Partners XII, L.P.; ARCH Venture Fund XII, L.P.; CRANDELL KEITH; NELSEN ROBERT; Burow Kristina; GILLIS STEVEN | 10% owner | Open-market purchase | 1,100,000 | $18.00 | $19.80M | Form 4 |
| 2026-05-04 | ARCH Venture Partners XII, LLC; ARCH Venture Partners XII, L.P.; ARCH Venture Fund XII, L.P.; CRANDELL KEITH; NELSEN ROBERT; Burow Kristina; GILLIS STEVEN | 10% owner | Conversion of derivative | 2,681,265 | — | — | Form 4 |
| 2026-05-04 | ARCH Venture Partners XII, LLC; ARCH Venture Partners XII, L.P.; ARCH Venture Fund XII, L.P.; CRANDELL KEITH; NELSEN ROBERT; Burow Kristina; GILLIS STEVEN | 10% owner | Conversion of derivative | 2,513,686 | — | — | Form 4 |
| 2026-05-04 | PAUL STEVEN M | Director | Conversion of derivative (derivative) | 210,526 | — | $0 | Form 4 |
| 2026-05-04 | PAUL STEVEN M | Director | Conversion of derivative | 67,031 | — | — | Form 4 |
| 2026-05-04 | Torres Denice | Director | Conversion of derivative (derivative) | 42,105 | — | $0 | Form 4 |
| 2026-05-04 | Torres Denice | Director | Conversion of derivative | 13,406 | — | — | Form 4 |
| 2026-05-04 | Chen Michael Cunyuan | Officer (Chief Scientific Officer) | Conversion of derivative (derivative) | 10,526 | — | $0 | Form 4 |
| 2026-05-04 | Chen Michael Cunyuan | Officer (Chief Scientific Officer) | Conversion of derivative | 3,351 | — | — | Form 4 |
| 2026-05-04 | Gladstein Lana | Officer (General Counsel) | Conversion of derivative (derivative) | 105,263 | — | $0 | Form 4 |
| 2026-05-04 | Gladstein Lana | Officer (General Counsel) | Conversion of derivative | 33,515 | — | — | Form 4 |
| 2026-05-04 | White Lauren | Officer (Chief Financial Officer) | Conversion of derivative (derivative) | 21,052 | — | $0 | Form 4 |
| 2026-05-04 | White Lauren | Officer (Chief Financial Officer) | Conversion of derivative | 6,702 | — | — | Form 4 |
| 2026-05-04 | HEALY JAMES | Director | Conversion of derivative (derivative) | 2,526,315 | — | $0 | Form 4 |
| 2026-05-04 | HEALY JAMES | Director | Conversion of derivative (derivative) | 6,052,631 | — | $0 | Form 4 |
| 2026-05-04 | HEALY JAMES | Director | Conversion of derivative | 804,379 | — | — | Form 4 |
| 2026-05-04 | HEALY JAMES | Director | Conversion of derivative | 1,927,159 | — | — | Form 4 |
| 2026-04-30 | Mates Sharon | Director | Grant / award / vesting (derivative) | 49,033 | — | $0 | Form 4 |
| 2026-04-30 | Loebel Antony | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 63,680 | — | $0 | Form 4 |
| 2026-04-30 | HOMBACH ROBERT J. | Director | Grant / award / vesting (derivative) | 12,258 | — | $0 | Form 4 |
| 2026-04-30 | PAUL STEVEN M | Director | Grant / award / vesting (derivative) | 991,192 | — | $0 | Form 4 |
| 2026-04-30 | PAUL STEVEN M | Director | Grant / award / vesting (derivative) | 12,258 | — | $0 | Form 4 |
| 2026-04-30 | Torres Denice | Director | Grant / award / vesting (derivative) | 12,258 | — | $0 | Form 4 |
| 2026-04-30 | Chen Michael Cunyuan | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 63,680 | — | $0 | Form 4 |
| 2026-04-30 | Gladstein Lana | Officer (General Counsel) | Grant / award / vesting (derivative) | 63,680 | — | $0 | Form 4 |
| 2026-04-30 | PETERSON SANDRA E | Director | Grant / award / vesting (derivative) | 12,258 | — | $0 | Form 4 |
| 2026-04-30 | Wheadon David E. | Director | Grant / award / vesting (derivative) | 12,258 | — | $0 | Form 4 |
| 2026-04-30 | White Lauren | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 63,680 | — | $0 | Form 4 |
| 2026-04-30 | Zohar Daphne | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 1,486,786 | — | $0 | Form 4 |
| 2026-04-30 | Zohar Daphne | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 271,813 | — | $0 | Form 4 |
Ask the chat about SPTX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Seaport Therapeutics, Inc. (SPTX).
Last updated 2026-06-22 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.